Physician profile
Luke W Chen
NPI 1265451736
$45,785.97
in general payments reported to CMS, 2019-2025
61 companies · $2,486 in 2025
The $2,486 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20K · 2020: $14K · 2021: $8,838 · 2022: $213 · 2023: $83.85 · 2024: $21.68 · 2025: $2,486.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,080 · Food and Beverage: $325 · Travel and Lodging: $120 · Education: $66.58.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,080.00 |
| Food and Beverage | $325.22 |
| Travel and Lodging | $119.93 |
| Education | $66.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $9,217.54 | 2019-2021 | |
| Seagen INC. | $6,155.34 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $5,191.97 | 2019-2020 | |
| Pfizer INC. | $3,570.60 | 2019-2025 | |
| Geron Corporation | $2,334.77 | 2025 | Imetelstat |
| Exelixis INC. | $2,212.23 | 2019-2021 | |
| Genentech USA, INC. | $2,068.17 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $2,007.49 | 2019-2021 | |
| Abbvie INC. | $1,740.71 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $1,185.44 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $1,045.14 | 2019-2021 | |
| Amgen INC. | $983.12 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $919.16 | 2019-2021 | |
| Janssen Biotech, INC. | $762.38 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $642.06 | 2019-2025 |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luke Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.